MEI Pharma (MEIP)

Recent filings

Mathew P. Arens just issued a filing suggesting it has sold all of its MEI Pharma - May 31, 2022

Mei Pharma Reports Third Quarter Fiscal Year 2022 Results And Operational Highlights - May 23, 2022

MEI Pharma Just Filed Its Annual Report: Net Loss Per ShareBa... - May 23, 2022

MEI Pharma Just Filed Its Quarterly Report: Note 5. Net Loss Per... - May 23, 2022

MEI Pharma Just Filed Its Quarterly Report: Note 5. Net Loss Per... - May 23, 2022

MEI Pharma Just Filed Its Quarterly Report: Note 5. Net (Loss) I... - May 23, 2022

Notification of inability to timely file Form 10-Q or 10-QSB - May 17, 2022

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or - May 13, 2022

Statement of acquisition of beneficial ownership by individuals - April 7, 2022

Mei Pharma And Kyowa Kirin Provide Regulatory Update On Zandelisib - March 25, 2022

Mathew P. Arens just provided an update on share ownership of MEI Pharma - Feb. 14, 2022

Statement of acquisition of beneficial ownership by individuals - Feb. 11, 2022

MEI Pharma Just Filed Its Quarterly Report: Note 5. Net Loss Per... - Feb. 10, 2022

BlackRock, Inc. just provided an update on share ownership of MEI Pharma - Feb. 9, 2022

Departure of Directors or Certain - Dec. 23, 2021

Amendments to Articles of Incorporation or - Dec. 17, 2021

Mei Pharma Announces Pricing Of Public Offering Of Common Stock San Diego - Dec. 6, 2021

MEI Pharma just filed a prospectus, suggesting it plans to soon issue some securities - Dec. 2, 2021

Mei Pharma And Kyowa Kirin Announce Data From The Ongoing Global Phase 2 Tidal Study Evaluating Zandelisib As A Single Agent In Patients With Relapsed Or Refractory Follicular Lymphoma - Nov. 30, 2021

MEI Pharma just filed a prospectus, suggesting it plans to soon issue some securities - Nov. 30, 2021

Mei Pharma Appoints Biotechnology Executive Sujay Kango To Its Board Of Directors - Nov. 23, 2021

MEI Pharma director was just granted 58,334 options - Nov. 23, 2021

MEI: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers - Nov. 23, 2021

MEI Pharma director just declared 0 ownership of the company. - Nov. 23, 2021

MEI Pharma Just Filed Its Quarterly Report: Note 5. Net Loss Per... - Nov. 10, 2021

MEI Pharma releases salary data. CEO sees compensation rise 30% - Oct. 28, 2021

MEI: Form, Schedule Or Registration Statement No Filing Party: Date Filed:  Counts! MEI PHARMA, INC. - Oct. 28, 2021

Other preliminary proxy statements - Oct. 6, 2021

MEI Pharma Just Filed Its Annual Report: Net Loss Per ShareBa... - Sept. 2, 2021

Mei Pharma Announces Planned Chief Financial Officer Transition - Aug. 5, 2021

MEI Pharma's Chief Medical Officer was just granted 320,000 options - July 6, 2021

MEI Pharma director was just granted 50,000 options - July 6, 2021

MEI Pharma director was just granted 50,000 options - July 6, 2021

MEI Pharma's Chief Executive Officer just disposed of 41,320 shares - July 6, 2021

MEI Pharma director was just granted 50,000 options - July 6, 2021

MEI Pharma's Chief Operating Officer & GC just disposed of 24,825 shares - July 6, 2021

MEI Pharma's Chief Financial Officer was just granted 200,000 options - July 6, 2021

MEI Pharma director was just granted 50,000 options - July 6, 2021

MEI Pharma director was just granted 50,000 options - July 6, 2021

MEI Pharma director was just granted 50,000 options - July 6, 2021

MEI Pharma director was just granted 50,000 options - July 6, 2021

MEI Pharma director was just granted 50,000 options - July 6, 2021

Current report, items 8.01 and 9.01 - June 14, 2021

Statement of changes in beneficial ownership of securities - May 27, 2021

Securities to be offered to employees in employee benefit plans - May 6, 2021

MEI Pharma Just Filed Its Quarterly Report: The following table ... - May 6, 2021

MEI Pharma's Chief Medical Officer was just granted 75,000 options - May 5, 2021

MEI Pharma's Chief Medical Officer just declared owning 37,123 shares of MEI Pharma - May 5, 2021

Current report, items 5.02, 8.01, and 9.01 - April 30, 2021

Current report, items 2.02, 8.01, and 9.01 - April 13, 2021

MEI Pharma director just disposed of 25,000 shares - Feb. 24, 2021

Perceptive Life Sciences Master Fund, Ltd. just issued a filing suggesting it has sold all of its MEI Pharma - Feb. 16, 2021

Ansbert Gadicke just provided an update on share ownership of MEI Pharma - Feb. 16, 2021

Vivo Opportunity, LLC just provided an update on share ownership of MEI Pharma - Feb. 12, 2021

Mark N. Lampert just provided an update on share ownership of MEI Pharma - Feb. 11, 2021

Quarterly report [Sections 13 or 15(d)] - Feb. 4, 2021

BlackRock, Inc. just provided an update on share ownership of MEI Pharma - Feb. 2, 2021

Securities to be offered to employees in employee benefit plans - Jan. 8, 2021

Departure of Directors or Certain - Dec. 17, 2020

Sorry, no schedule available for this company

MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 - March 8, 2022

MEI Pharma Announces Acceptance of Two Abstracts for Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 - March 8, 2022

MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - March 1, 2022

MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - March 1, 2022

MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights - Feb. 10, 2022

MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights - Feb. 10, 2022

MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments - Feb. 7, 2022

MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments - Feb. 7, 2022

MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Feb. 1, 2022

MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Feb. 1, 2022

MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan. 3, 2022

MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan. 3, 2022

MEI Pharma Announces Closing of Public Offering of Common Stock - Dec. 6, 2021

MEI Pharma Announces Closing of Public Offering of Common Stock - Dec. 6, 2021

MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec. 3, 2021

MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec. 3, 2021

MEI Pharma Announces Pricing of Public Offering of Common Stock - Dec. 1, 2021

MEI Pharma Announces Pricing of Public Offering of Common Stock - Dec. 1, 2021

MEI Pharma Announces Proposed Public Offering of Common Stock - Nov. 30, 2021

MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma - Nov. 30, 2021

 


Feedback